Morningstar - F5 Networks Inc. (FFIV) F5 Continues Mild and Decelerating Growth in 2Q; Maintaining our $126 FVE

Report

Morningstar

Ali Mogharabi

F5 Continues Mild and Decelerating Growth in 2Q; Maintaining our $126 FVE

F5 Networksâ€™ second quarter continued mild year-over-year revenue and operating margin growth. Software and Services supported the mild growth as Products, which includes Software, saw an overall decline. We are maintaining our $126 fair value estimate for this narrow-moat company.
Revenue of $533 million was up 2.9% year over year, but again marked growth deceleration. Growth came only from the Services division, which increased 7% year over year. While software revenue grew a considerable 28% ...

26/04/2018 12 EN

Underlying

F5 Networks Inc.

F5 Networks is a provider of multi-cloud application services, which enable its customers to develop, deploy, operate, secure, and govern applications in any architecture, from on-premises to the public cloud. The company's application services are available as cloud-based, software-as-a-service, and software-only solutions supported for multi-cloud environments. In connection with its solutions, the company provides a range of services, including consulting, training, installation, maintenance, and other technical support services. The company's products and solutions include hardware platforms, software and software-as-a-service platforms, cloud-based managed services, and service provider solutions.

See profile

US3156161024 NASDAQ Stock Market United States

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Ali Mogharabi

Other Reports on these Companies

TheScreener

F5 sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of F5 (US), active in the Telecommunications Equipment industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date January 18, 2022, the closing price was USD 223.50 and its target price was estimated at USD 202.04.

Free Trial

January 19, 2022 January 19, 2022 1 EN

Valens Research

Valens Equity Insights and Inflections - 2021 10 19

Hillenbrand (HI) has pivoted successfully to roll-up the industrial machinery industry in the past decade, giving the business greater growth potential and opportunities for asset efficiency. Uniform Accounting highlights these efficiency improvements that the market is missing, indicating equity upside. Over the last decade, Hillenbrand has expanded its business from a casket business into the industrial machinery industry, causing Uniform ROA to improve to stable 25%-28% levels. It has acquired its way into industrial machinery, and while the market appears concerned about its recent Mil...

October 20, 2021 October 20, 2021 27 EN

Valens Research

FFIV - Embedded Expectations Analysis - 2021 10 15

F5 Networks, Inc. (FFIV) currently trades above historical and corporate averages relative to Uniform earnings, with a 28.4x Uniform P/E (Fwd. V/E'). At these levels, markets are pricing in expectations for Uniform ROA to gradually recover back to 2019 levels of 28%, accompanied by 5% Uniform asset growth. Meanwhile, analyst expectations for 21% Uniform ROA and 4% Uniform asset growth imply a stock price approaching $157, representing 23% equity downside for the firm. Moreover, the firm's most recent earnings call suggests management may have concerns about their growth, software business, ...

October 16, 2021 October 16, 2021 10 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Joe Gemino

Joe Gemino

Sasol Provides Full-Year Production Update

No-moat Sasol provided an update on its full-year fiscal 2019 production metrics that included relatively stable liquids production. For the full year ended June 30, Sasol produced 1,470 thousand barrels of crude oil and condensate a day compared with 1,469 mboe/d in the year-ago period. However, declines continued with the companyâ€™s natural gas production, down 4% to 130.3 billion cubic feet compared with the period ended June 30, 2018. Sasol also reported flat refined products of 31.4 mmboe/d ...

EUR 100.00

July 25, 2019 July 25, 2019 12 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

F5 Continues Mild and Decelerating Growth in 2Q; Maintaining our $126 FVE

F5 sees a downgrade to Slightly Negative on account of less fundamental stars

Valens Equity Insights and Inflections - 2021 10 19

FFIV - Embedded Expectations Analysis - 2021 10 15

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Sasol Provides Full-Year Production Update

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe